Fate Therapeutics shares rise 3% after-hours following new employee inducement grants.

Fate Therapeutics, Inc. rose 3% in after-hours trading, with the company announcing that it granted non-qualified stock options to a newly-hired non-executive employee to purchase 45,000 shares of the Company’s common stock at an exercise price per share of $1.03. The company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders.